Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

Tim Draper On The AI Boom, Bitcoin’s Future And Building ‘Human Accelerators’

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: Tim Draper On The AI Boom, Bitcoin’s Future And Building ‘Human Accelerators’ Date: 2026-03-06 12:00 Source: https://news.crunchbase.com/venture/tim-draper-ai-bitcoin-human-accelerators/ <p>Few venture capitalists have the name recognition — or tenure — of <a href="https://www.crunch…
Opening lines of the source · Crunchbase News · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI will eventually be bigger than anyone imagined, especially in robotics

    80% confidence
  • Countries like El Salvador, Japan, Dubai and Abu Dhabi are thriving because they encourage crypto innovation

    80% confidence
  • The US made everything a security and illegal, causing crypto innovators to geofence the US to protect from the SEC

    80% confidence
  • Regulators should not regulate in anticipation of fearful outcomes, only after something bad happens

    80% confidence
  • Everything should be decentralized because the person on the ground knows better than centralized authorities

    80% confidence
  • Bitcoin is in a period where 'nobody cares' but it's slowly taking over

    80% confidence
  • Every industry goes through the Draper iS curve with initial hype, crash, and then sustained growth

    80% confidence
  • Healthcare is moving from chemotherapies to bio-cures like stem cells, cloning, and genetic engineering

    80% confidence
  • Space and transportation companies are now called dual-use and governments are buying because they're behind the commercial sector

    80% confidence
  • Bitcoin's perfect records could eliminate the need for 85,000 IRS agents

    80% confidence
  • The most important founder trait is a love and obsession for the customer

    80% confidence
  • Draper University is a 'human accelerator' not a 'pre-accelerator' because it accelerates people, not businesses

    80% confidence
  • The big early internet winners (AOL, Yahoo, Netscape) didn't end up being a big part of the internet later

    80% confidence
  • Coca-Cola hires people based on specific voice models that match desired personality types

    80% confidence
  • Quantum computers will hack banks before bitcoin because banks are easier to hack

    80% confidence
  • Laws should sunset and the '33 and '40 Acts are keeping the poor poor and the rich rich

    80% confidence
  • The current AI boom is as big as the dot-com boom, maybe bigger

    80% confidence
  • Eventually retailers will say 'We only take bitcoin' and there will be a run on the dollar

    80% confidence
  • Meet the Drapers had a reach of 300 million people with 10 million seeing each episode

    80% confidence
  • One or two general AI companies will become 'hungry giants' and acquire companies working around the edges

    80% confidence
  • AI is right at the 'dot' on the i or coming down from the hype peak due to energy issues

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com